CEVEC

Articles

Reduction of Product-related Impurities during Production of recombinant Adeno-Associated Viruses

Petra Nitschke is your initial point of contact for CEVEC. Before joining the company in 2019 she held various positions in Business Development, Marketing and Finance, both, in large multinational corporations, including Novartis, as well as in a Bio-Engineering startup.
email: bizdev@cevec.com

Introduction of ELEVECTA®, CEVEC’s fully scalable and stable production platform for AAV gene therapy viral vector manufacturing.